News Story

FDA Acting Commissioner Visits Bioengineering

Andrew von Eschenbach, M.D., Acting Commissioner of the FDA.

Andrew von Eschenbach, M.D., Acting Commissioner of the Food and Drug Administration (FDA), met with University of Maryland President Dr. C.D. Mote, Jr. and other campus representatives on September 7, and toured bioengineering laboratories in the Jeong H. Kim Engineering Building.

Dr. von Eschenbach visited campus to learn more about the relationship between the FDA and the University of Maryland, and to explore ways in which the two organizations could enhance their collaboration, particularly since the FDA will be relocating to White Oak, Md., only 5 miles from College Park. Dr. von Eschenbach toured the labs of Drs. Hsieh and Fisher in the Fischell Department of Bioengineering, as well as the planned site for the new bioengineering wing in the Kim Engineering Building. He commented on the value of research interactions already in place between UMCP and the FDA, and the importance of connecting the FDA with the graduate and new undergraduate programs in bioengineering so future engineers could gain insight into and experience with the FDA and its mission in fostering human health.

To learn more about the FDA/University of Maryland initiative, including information on related undergraduate and graduate internships and fellowships, postdoctoral positions, and research sabbaticals for faculty, you may download the overview (in PDF format) from:

http://www.umresearch.umd.edu/oraa/whats_new/FDA_BIO_Ad.pdf

September 14, 2006